Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of “Moderate Buy” by Analysts

Zealand Pharma A/S (OTCMKTS:ZLDPF) has been assigned an average rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and three have given a strong buy rating to the company.

ZLDPF has been the subject of a number of analyst reports. BNP Paribas Exane cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF stock opened at $43.65 on Thursday. The business’s 50 day moving average is $53.95 and its two-hundred day moving average is $67.11. The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02. Zealand Pharma A/S has a twelve month low of $35.93 and a twelve month high of $83.12. The company has a market capitalization of $3.10 billion, a P/E ratio of 3.19 and a beta of 0.88.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.34) by $0.53. Zealand Pharma A/S had a return on equity of 48.10% and a net margin of 70.06%.The firm had revenue of $10.79 million during the quarter, compared to analyst estimates of $19.69 million. Equities analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.